<DOC>
	<DOCNO>NCT00402012</DOCNO>
	<brief_summary>This study design look effect Pioglitazone treatment body 's ability burn food order produce energy .</brief_summary>
	<brief_title>`` TAKE TIME '' Pioglitazone Reverses Defects Mitochondrial Biogenesis Patients With T2DM</brief_title>
	<detailed_description>Skeletal muscle mitochondrial defect sine qua non insulin resistance patient T2DM . Pioglitazone decrease free fatty acid level restore mitochondrion number adipose tissue whereas high fat diet lipid infusion decrease gene involve mitochondrial biogenesis . Increased lipid flux diet adipose tissue skeletal muscle might cause decreased mitochondrial biogenesis . The purpose study determine 22 week treatment Pioglitazone increase mitochondrial biogenesis muscle 30 uncomplicated T2DM patient previously take TZD 's . This Phase IV , randomize , double-blind , placebo control , clinical trial consist 3 phase : screening , placebo / Pioglitazone phase ( 12 week ) weight loss period ( 6-10 week ) . The primary endpoint identify change skeletal muscle mitochondrion number gene expression . Secondary endpoint include MRS measure mitochondrial capacity , insulin sensitivity glucose disposal insulin suppression free fatty acid , electron transport chain activity , mitochondrial content intra hepatic intra myocellular lipid . Metformin Sulfonylurea use standardized oral therapy maintain HbA1C &lt; 7.0 . After complete protocol , patient offer low calorie liquid diet ( 800kcal/d ) assist lose weight . During period continue previously randomize treatment . When patient lose 10 % body weight , patient switch weight maintenance diet ( meal replacement 1 glucerna breakfast lunch `` healthy '' dinner ) 10 day . MRS measure mitochondrial capacity determine see weight loss + pioglitazone effect mitochondrial function pioglitazone alone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Men woman age 1870 Type 2 diabetes define : Fasting plasma glucose &gt; 126 mg/dL entry Or twohour OGTT glucose &gt; 200mg/dL Or current treatment one two oral antidiabetic drug , except TZD Or currently use insulin Fasting plasma glucose &lt; 200mg/dL entry BMI &gt; 27.0 &lt; 45.0kg/m2 Adequate contraception woman ( include , limited : oral contraception , hysterectomy , tubal ligation , postmenopausal define &gt; 6 month without menstrual cycle FSH &gt; 40 mIU/ml ) . Significant renal , cardiac , liver , lung , neurological disease ( control hypertension acceptable baseline bp &lt; 140/90 medication ) . Prior use thiazolidinediones ( rosiglitazone [ AVANDIATM ] , pioglitazone [ ACTOSTM ] ) Use drug know affect energy metabolism body weight : include , limited : orlistat , sibutramine , ephedrine , phenylpropanolamine , corticosterone , etc . Pregnancy Alcohol drug abuse Unwilling unable abstain caffeine ( 48h ) tobacco ( 24h ) prior metabolic rate measurement Increased liver function test baseline ( AST/ALT/GGT/or alkaline phosphatase great 2.5 time upper limit normal ) Metal object would interfere measurement body composition /MRS implant rod , surgical clip , etc . HbA1C &gt; 10 % . NYHA class III/IV CHF exclusionary cardiac condition . history deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) varicose vein major surgery abdomen , pelvis , low extremity within previous 3 month cancer ( active malignancy without concurrent chemotherapy ) rheumatoid disease bypass graft limb know genetic factor ( Factor V Leiden , etc ) hypercoagulable state diagnose peripheral arterial vascular disease , intermittent claudication family history primary DVT PE ( pulmonary embolism ) peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
</DOC>